Stroke is the second highest cause of death globally and a leading cause of disability, with
an increasing incidence in developing countries. Ischaemic stroke caused by arterial …

Background Stroke thrombolysis with alteplase is currently recommended 0–4·5 h after
stroke onset. We aimed to determine whether perfusion imaging can identify patients with …

Background Results of initial randomised trials of endovascular treatment for ischaemic
stroke, published in 2013, were neutral but limited by the selection criteria used, early-…

Background Trials of endovascular therapy for ischemic stroke have produced variable
results. We conducted this study to test whether more advanced imaging selection, recently …

Background In 2015, five randomised trials showed efficacy of endovascular thrombectomy
over standard medical care in patients with acute ischaemic stroke caused by occlusion of …

Endovascular therapy (EVT) for acute ischemic stroke in selected patients has recently been
proven effective in several clinical trials, and the widespread adoption of thrombectomy into …

2982 Stroke October 2015 threshold between PH1 and PH2 was not clarified. 10 Regardless,
in the ECASS, only PH2, but not PH1 or HI, was associated with early deterioration and 3-…

Background The time to initiate intravenous thrombolysis for acute ischemic stroke is generally
limited to within 4.5 hours after the onset of symptoms. Some trials have suggested that …

Background Intravenous infusion of alteplase is used for thrombolysis before endovascular
thrombectomy for ischemic stroke. Tenecteplase, which is more fibrin-specific and has longer …

Background Nerinetide, an eicosapeptide that interferes with post-synaptic density protein
95, is a neuroprotectant that is effective in preclinical stroke models of ischaemia-reperfusion. …